Journal article
Three-month efficacy and safety of once-daily diltiazem in chronic stable angina pectoris
Abstract
The 3-month efficacy and safety of a once-daily controlled formulation of diltiazem (180 to 360 mg/day) were assessed in a study of 54 patients with angina pectoris. This multicenter study was a nonrandomized, placebo run-in, open-label, 3-month trial followed by a 1-week, double-blind, randomized period during which most patients (89%) received placebo. There were only minimal changes in the time to termination (mean change +/- SEM -5.8 +/- …
Authors
Nadeau C; Hilton D; Savard D; Morin Y; Baird M; Alexander M; Langer G; Roth D; Boulet AP; Larivie`re L
Journal
The American Journal of Cardiology, Vol. 75, No. 8, pp. 555–558
Publisher
Elsevier
Publication Date
March 1995
DOI
10.1016/s0002-9149(99)80615-8
ISSN
0002-9149